Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Hologic Inc Market Cap
From what 19 stock analysts predict, the share price for Hologic Inc (HOLX) might increase by 10.43% in the next year. This is based on a 12-month average estimation for HOLX. Price targets go from $82 to $96. The majority of stock analysts believe HOLX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Hologic Inc has a total of 19 Wall St Analyst ratings. There are 14 buy ratings, 5 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Hologic Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of HOLX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Anthony Petrone Mizuho | Outperform | $90 | Maintains | Oct 4, 2024 |
| Patrick Donnelly Citigroup | Neutral | $85 | Downgrade | Oct 1, 2024 |
| Vijay Kumar Evercore ISI Group | In-Line | $82 | Maintains | Oct 1, 2024 |
| Mike Matson Needham | Buy | $90 | Reiterates | Sep 17, 2024 |
| Conor McNamara RBC Capital | Sector Perform | $82 | Reiterates | Aug 16, 2024 |
| Mike Matson Needham | Buy | $90 | Reiterates | Jul 30, 2024 |
| Conor McNamara RBC Capital | Sector Perform | $82 | Maintains | Jul 30, 2024 |
| Vijay Kumar Evercore ISI Group | In-Line | $78 | Maintains | Jul 30, 2024 |
| Mason Carrico Stephens & Co. | Overweight | $92 | Reiterates | Jul 30, 2024 |
| Casey Woodring JP Morgan | Overweight | $95 | Maintains | Jul 30, 2024 |
| Vijay Kumar Evercore ISI Group | In-Line | $76 | Maintains | Jul 2, 2024 |
| Mason Carrico Stephens & Co. | Overweight | $87 | Initiates | Jun 27, 2024 |
| David Toung Argus Research | Buy | $95 | Maintains | May 9, 2024 |
| Casey Woodring JP Morgan | Overweight | $91 | Maintains | May 3, 2024 |
| Mike Matson Needham | Buy | $90 | Reiterates | May 3, 2024 |
| Mike Matson Needham | Buy | $90 | Reiterates | Apr 10, 2024 |
| Vijay Kumar Evercore ISI Group | In-Line | $78 | Maintains | Apr 4, 2024 |
| Patrick Donnelly Citigroup | Buy | $95 | Upgrade | Apr 3, 2024 |
| Andrew Cooper Raymond James | Outperform | $88 | Maintains | Feb 2, 2024 |
| Mike Matson Needham | Buy | $90 | Maintains | Feb 2, 2024 |
When did it IPO
1990
Staff Count
6,990
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Mr. Stephen P. MacMillan
Market Cap
$18.64B
In 2023, HOLX generated $4.03B in revenue, which was a decrease of -17.12% from the previous year. This can be seen as a signal that HOLX's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 30 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Hologic (HOLX) is attracting attention from Zacks.com users, indicating potential interest in the stock's future performance and investment prospects.
Why It Matters - Increased interest in Hologic (HOLX) suggests potential volatility or upcoming developments, signaling investors to monitor the stock for possible investment opportunities or risks.
Mon, 30 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Hologic launched the #BustTheMyth campaign to debunk breast cancer myths and empower women during Breast Cancer Awareness Month.
Why It Matters - Hologic's campaign may enhance brand reputation and drive product demand, positively impacting sales and stock performance, particularly in the healthcare sector.
Fri, 27 Sep 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Hologic shows strong potential in Molecular Diagnostics, but may face challenges due to macroeconomic uncertainties affecting its operations.
Why It Matters - Hologic's growth potential in Molecular Diagnostics may drive future profits, but macroeconomic uncertainties could impact revenue stability and overall investment risk.
Fri, 27 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Hologic expands its breast health product line to include imaging, biopsy, and surgery, enhancing its comprehensive breast cancer care offerings.
Why It Matters - Hologic's expanded product range enhances its market position in breast cancer care, potentially increasing revenue streams and attracting investor interest in its growth prospects.
Tue, 24 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Zacks Premium offers Style Scores to help value, growth, and momentum investors identify strong stocks more easily.
Why It Matters - The Zacks Style Scores enhance stock selection across investment strategies, potentially leading to better returns and informed investment decisions.
Fri, 20 Sep 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Hologic (HOLX) closed at $81.39, reflecting a decline of 1.23% from the previous trading day.
Why It Matters - Hologic's stock decline signals potential concerns about its performance or market perception, which may affect investor sentiment and future trading decisions.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
